Clinical trials: Malignant Tumors, active
Ependymoma
HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma
This is a Phase I study to evaluate the safety profile of a type of immune therapy called HER2 CAR T cells (short for HER2 chimeric antigen receptor T cells).
- Trial name
- NCT04903080
- Testing
- HER2 Specific CAR T Cell
- Where
- 13 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Children's Oncology Group
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy
The main goal of this study is to investigate the effectiveness and safety of chemotherapy agents in the treatment of participants with BPDCN and to provide comparator arm data to the prospective ELZONRIS registry study…
- Trial name
- NCT07785180
- Testing
- Chemotherapy
- Where
- 67 sites in Denmark, France and 9 more
- Volunteers
- 140 people
- Sponsor
- Stemline Therapeutics, Inc.
Metastatic Melanoma
TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma
This is an open-label, phase 1 trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with lymphocyte-depleting chemotherapy and TILs in metastatic melanoma patients.
- Trial name
- TUNINTIL-2 (NCT06961786)
- Testing
- TILT-123, TIL, Cyclophosphamide
- Where
- Denmark
- Volunteers
- 9 people
- Sponsor
- TILT Biotherapeutics Ltd.
Lung Carcinoma, Lung Non-Small Cell Carcinoma
Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
This phase II trial tests the effectiveness and safety of artificial intelligence (AI) to determine dose recommendation during stereotactic body radiation therapy (SBRT) planning in patients with primary lung cancer or tumors…
- Conditions
- Lung Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Lung, Stage I Lung Cancer AJCC v8
- Trial name
- NCT05802186
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Northwestern University
Advanced Solid Tumor, Metastatic Solid Tumor
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
This is a first-in-human Phase 1a/b, open-label, multicenter, dose escalation, optimization and expansion study of ISM5939 to evaluate the safety, tolerability, PK, PD, and preliminary antitumor activity of ISM5939 in patients…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Advanced and/or Metastatic Solid Tumors
- Trial name
- NCT06724042
- Testing
- ISM5939, Cisplatin, Docetaxel
- Volunteers
- 159 people
- Sponsor
- InSilico Medicine Hong Kong Limited
Advanced Solid Tumors
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
The purpose of this trial is to learn about the safety and effectiveness of the antibody GEN1079 in participants with certain types of cancer. The trial has multiple parts.
- Trial name
- NCT07387068
- Testing
- GEN1079
- Where
- 12 sites in United States, Spain
- Volunteers
- 121 people
- Sponsor
- Genmab
Patients With Advanced Solid Tumors
Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors
This study is a Phase I clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor efficacy of LNF2105 in patients with advanced solid tumors.
- Trial name
- NCT07661797
- Testing
- LNF2105(Antibody-Drug Conjugate (ADC) targeting Nectin-4)
- Volunteers
- 294 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
This phase I trial tests the safety, side effects and best dose of BAY 1895344 when given together with usual chemotherapy (irinotecan or topotecan) in treating patients with solid tumors that may have spread from where it first…
- Conditions
- Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT04514497
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 23 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor
A First-in-Human Study of BG-92505 Alone or in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
The purpose of this study is to test if the BG-92505 is safe and if it works in patients with advanced solid tumors when it is given on its own or in combination with anti-cancer agents.
- Trial name
- NCT07896460
- Testing
- BG-92505, Anti-Cancer Agent
- Volunteers
- 137 people
- Sponsor
- BeOne Medicines
Solid Tumors With FGFR2 Alterations, Adult
A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
This is a Phase1, open-label, dose escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of KNT-0916 in patients with unresectable or metastatic…
- Trial name
- NCT06800196
- Testing
- KNT-0916
- Where
- China
- Volunteers
- 151 people
- Sponsor
- KinoTeck Therapeutics Co., Ltd
Neuroendocrine Tumors, Progression
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Everolimus is approved in many countries to treat patients with advanced/metastatic well-differentiated neuroendocrine tumors (NET), providing median progression-free survival times of approximately 12 months across different…
- Conditions
- Neuroendocrine Tumors, Progression, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2
- Trial name
- EVENET (NCT06472388)
- Testing
- Everolimus 5 MG
- Where
- 2 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- AC Camargo Cancer Center
Glioma
Protoporphyrin Imaging in Multispectral Evaluation of Resections
Observational non-interventional investigation to evaluate the potential of multispectral imaging in improving tumor visualization.
- Trial name
- PRIMER (NCT07021573)
- Testing
- KINEVO 900 S with BLUE 400
- Where
- 10 sites in Austria, Germany and 1 more
- Volunteers
- 80 people
- Sponsor
- Medical University Innsbruck
Cancer
Real-World Study of Young Patients With Solid Tumors in China
To evaluate organ preservation rates, fertility preservation, and long-term quality of life after treatment among young patients.
- Trial name
- NCT07708935
- Testing
- Ages 18-40
- Where
- China
- Volunteers
- 12,000 people
- Sponsor
- Fudan University
Glioblastoma, Glioblastoma Multiforme
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination.
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioma, Malignant, GBM
- Trial name
- NCT05271240
- Testing
- Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation, Temozolomide and Radiation Alone
- Where
- United States
- Volunteers
- 432 people
- Sponsor
- Northwell Health
Newly Diagnosed MGMT Unmethylated Glioblastoma
D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
The purpose of this research study is to determine the safety and efficacy of administering a single intracerebral (within the brain) dose of investigational compounds called D2C7-immunotoxin (IT) and 2141-V11 in residual disease…
- Trial name
- NCT05734560
- Testing
- D2C7-IT, 2141-V11
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Darell Bigner
Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm
Testing the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy
This phase II trial studies whether using exercise is better than the usual approach for treating chemotherapy-induced peripheral neuropathy (CIPN).
- Conditions
- Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- CIPN (NCT04888988)
- Testing
- Best Practice, Exercise Counseling, Exercise Intervention
- Where
- 93 sites in United States
- Volunteers
- 133 people
- Sponsor
- University of Rochester NCORP Research Base
Ovarian Cancer
A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine
This is a phase 1 dose escalation trial of monotherapy misetionamide (also known as GP-2250) currently enrolling patients with platinum-resistant ovarian cancer (PROC) into Part 2 of the study.
- Trial name
- MIROC-1 (NCT03854110)
- Testing
- misetionamide (also known as GP-2250)
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Persevere Therapeutics Inc.
Malignant Neoplasm of Stomach, Unspecified
Clinical Study to Evaluate the Safety and Anti-Tumor Activity of AB-201
HER2 is highly expressed on the surface of several cancer types, including breast and gastric/gastroesophageal junction (GEJ) cancers.
- Trial name
- NCT07333820
- Testing
- AB-201 Dose escalation
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- Yonsei University
Colorectal Cancer, Non-Small Cell Lung Cancer
A Phase 1 Study of IM-1340 in Participants With Advanced Cancer
This study will test the safety and effectiveness of a drug called IM-1340 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with…
- Conditions
- Colorectal Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Neuroendocrine Neoplasm
- Trial name
- NCT07890246
- Testing
- IM-1340
- Volunteers
- 200 people
- Sponsor
- Immunome, Inc.
Malignant Neoplasm
68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study
68Ga-JH12 is a novel radiotracer targeting C-X-C motif chemokine receptor 4 (CXCR4). In this study, we observed the safety, biodistribution, and radiation dosimetry of 68Ga-JH12 in patients with different types of cancer.
- Trial name
- NCT06688188
- Testing
- 68Ga-JH12
- Where
- China
- Volunteers
- 5 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.